Safety and Efficacy of PRX-102 in Patients With Fabry Disease Currently Treated With REPLAGAL® (Agalsidase Alfa)
Clinical trial NCT03018730 · COMPLETED
Trial details
- NCT number
- NCT03018730
- Sponsor
- Protalix
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2017-05-17
- Primary completion
- 2019-12-17
- Enrollment
- 22
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.